EMA ETF Recommends COVID-19 Vaccine Reformulation to Target XFG Variant for 2026/2027 Campaign

Marketing authorisation holders for COVID-19 vaccines face mandatory composition updates after EMA's Emergency Task Force (ETF) formally recommended reformulating authorised vaccines to target the XFG SARS-CoV-2 variant ahead of the 2026/2027 vaccination campaign. The directive to contact EMA immediately to discuss marketing authorisation amendments signals an accelerated submission cycle for regulatory and manufacturing teams.

XFG is a JN.1-family Omicron subvariant that reached 74% of globally sequenced infections in October 2025, making it the dominant circulating strain. The ETF's recommendation is grounded in animal-study data comparing XFG-, LP.8.1-, and BA.3.2.2-adapted candidate vaccines, alongside real-world effectiveness data for vaccines containing JN.1/KP.2 and LP.8.1 strains. The evidence base indicates XFG-targeting provides the broadest protection across JN.1 subvariants and cross-protection against the genetically distinct BA.3.2 lineage, which is increasing in several EU member states.

LP.8.1-based vaccines retain conditional acceptability for 2026 campaigns, offering MAHs with advanced LP.8.1 programmes a limited transitional pathway. However, the ETF explicitly flagged BA.3.2's immune-evasion potential as a surveillance trigger: if BA.3.2 circulation increases substantially, the strain composition recommendation may be revised before the campaign window closes. Plant heads managing fill-finish scheduling and bulk antigen production should treat that contingency as a live planning variable, not a remote scenario.

For companies developing pipeline COVID-19 vaccines currently targeting strains other than XFG, the ETF has issued a parallel instruction to engage EMA on composition-change strategies. Under 21 CFR Part 211 equivalents in the EU GMP framework and ICH Q10 lifecycle management principles, strain substitutions in authorised biologics typically require a Type II variation or equivalent major change submission, with associated process validation and comparability data packages. The timeline pressure is material: national EU authorities retain final authority over campaign scheduling, and procurement decisions will follow regulatory clearance.

The recommendation will be reviewed if the epidemiological picture shifts, with BA.3.2 evolution and NB.1.8.1 co-circulation identified as the primary monitoring parameters. Regulatory teams should initiate pre-submission meetings with EMA without delay to scope the data requirements and lock in submission timelines that align with national campaign procurement windows.

Source: European Medicines Agency (EMA) via ema.europa.eu, 29 May 2026.